Evidence-based Pharmacotherapy; Clinical Pharmacology; Pharmacoepidemiology
Education
2000-2003 M.D./Ph.D. in Clinical Pharmacology, Pharmacoepidemiology, School of Pharmacy, Fudan University
1994-1997 M.S. in Clinical Pharmacology, Institute of clinical pharmacology, Anhui Medical University
1989-1994 B.S. in Clinical Medicine, Faculty of Medicine, Anhui Medical University
Professional Experiences
2006-present Associate Professor, PI, Supervisor of Postgraduate, School of Pharmacy, Fudan University
PI: Research Group of Evidence-based Pharmacotherapy
2008-2009/2015-2017 Visiting Associate Professor, Department of Pharmacology and Therapeutics, Medicine, University of British Columbia
Therapeutics Initiative, UBC
Cochrane Hypertension Group, Cochrane Collaboration
2003-2005 Lecturer, Assistant PI, School of Pharmacy, Shanghai Jiao Tong University
1997-2000 Clinical Pharmacologist and Head of TDM Laboratory, Anhui Provincial Hospital
1993-1994 Hospital Internship, Department of internal medicine, surgery, obstetrics & gynecology, and pediatrics, First Affiliated Hospital, Anhui Medical University
Teaching activities
Founder of a MOOC:
2014-2015 Creating a MOOC (Massive Open Online Course) “Antibacterial and Superbug ─ Gaming between Angel and Devil”, the first MOOC in natural science field at Fudan University, and successfully launching this MOOC both at home and abroad with more than 20,000 course learners online so far
1. This course is now open as an online course on COURSERA (world's largest MOOC Platform created in the USA)
2. This course is now open as an online course on iCOURSE (China's top MOOC Platform) at the same time
Courses taught:
Clinical Pharmacology, Basic Pharmacology, Pharmacoepidemiology, Basics of Diagnostics, Antibacterial and Super Bug, Pharmaceutical Comprehensive Knowledge and Skills, Pharmacology Lab, Pharmacoeconomics, Human Anatomy and Physiology
Grants & Projects
As Principal Investigator in scientific research project:
2008-present: Principal Investigator supported by Cochrane Hypertension Review Group of Cochrane Collaboration
First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension (A088)
Renin inhibitors versus angiotensin converting enzyme inhibitors for primary hypertension (A162)
Renin inhibitors versus angiotensin converting enzyme inhibitors for primary hypertension (A162)
Blood pressure lowering efficacy of drugs inhibiting the renin-angiotensin system as second-line therapy for primary hypertension (A071)
2016-2018: Principal Investigator sponsored by Shanghai Municipal Commission of Health and Family Planning (201640086)
Evidence-based pharmacotherapy of intervention with rennin-angiotensin system inhibitors plus calcium channel blockers to prevent clinical endpoints in hypertensive patients
2014-2017: Principal Investigator sponsored by Scientific Research Foundation for the Promising Scholars of Fudan University
Evidence-based pharmacotherapy of interventions with hypertensive drugs to prevent clinical endpoints in isolated systolic hypertensive patients
2013-2015: Principal Investigator sponsored by Shanghai Municipal Commission of Health and Family Planning (20124432)
Cochrane systematic review on first-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension
2006-2013: Principal Investigator sponsored by Science Foundation for the Excellent Youth Scholars of Fudan University
Association study of polymorphisms in the cyclooxygenase-2 gene and Alzheimer's disease risk in Chinese
2004-2007: Principal Investigator sponsored by Natural Science Foundation of Shanghai Science and Technology Committee (04ZR14084)
Study of the associations between polymorphisms within the COX genes and Alzheimer’s disease and responsiveness to NSAIDs therapy
2004-2005: Principal Investigator sponsored by Scientific Research Foundation for Intramural Young Teachers of Shanghai Jiao Tong University
Role of novel nicotinic receptor agonist in the treatment of experimental Alzheimer's disease
1997-2000: Principal Investigator supported by Anhui Provincial Hospital
Determination of Phenobarbital, Phenytoin and Carbamazepine in serum by RP-HPLC.
As Major Participant in scientific research project:
2007: Second Participant sponsored by National Natural Science Foundation of China, NSFC (30672460)
Study on molecular mechanism of paracetamol in promoting vascularization in the peri-infarct area of myocardial ischemia
2004-2006: Second Participant sponsored by a grant from the Shanghai R&D Public Service Platform Program of Shanghai Science and Technology Committee
Pharmacoepidemiological study of drug utilization in the elderly in Shanghai and the building of a big record linkage database system
2006-2008: Participant sponsored by National Natural Science Foundation of China, NSFC (30572179) 0
Effects of Activation of nicotinic receptor on APP processing
2005-2007: Participant sponsored by Natural Science Foundation of Shanghai (05JC14044)
Standard of TCM syndromes on primary hepatic carcinoma and effect of alkynol on liver cancer
As Principal Investigator in teaching project:
2016-2018: Principal Investigator of key project supported by Online Education Research Foundation of Ministry of Education, China (2016ZD311)
Curriculum construction of MOOCs* "Antibacterial and Super Bug" & teaching practice and research of "flipped classroom"
2014-2015 Principal Investigator of key project in the incentive programs on undergraduate course teaching and the educational reform supported by Fudan University (2013-14)
Curriculum construction of MOOCs* "Antibacterial and Super Bug" & teaching practice and research of "flipped classroom"
As Major Participant in teaching project:
2012-2013 Participant of undergraduate teaching research project supported by Fudan University (2012-64)
Exploration of the cultivation model to improve scientific research quality of undergraduates majored in pharmacy
Awards & Honors
2017 Excellent Graduate Thesis Award (Tutor), Fudan University (for the thesis “Evidence-based pharmacotherapy of interventions with hypertensive drugs to prevent clinical endpoints in isolated systolic hypertensive patients”)
2016 Nominee for the “National Outstanding Teacher of the Year 2016” Award, China
2016 First Class Award for Excellent Paper, the 2016’s National Pharmacoepidemiology Symposium, China (for the paper “Levodopa Compared with Dopamine Agonists Therapy as Initial Treatment for Parkinson’s Disease: a Meta Analysis and Cost-Effectiveness Analysis”)
2015 Creator of the first Massive Open Online Course (MOOC) in natural science field at Fudan University (for the MOOC “Antibacterial and Superbug ─ Gaming between Angel and Devil”)
2015 Received an invitation to record a podcast of one of my Cochrane Reviews - First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
(Of some 5,000 reviews published in The Cochrane Library there are only 250 podcasts, which shows that this is a very selective invitation.)
2015 Award for Outstanding Teacher, Fudan University
2014 Excellent Graduate Thesis Award (Tutor), Fudan University (for the thesis “Evidence-based pharmacotherapy of intervention with rennin-angiotensin system inhibitors to prevent clinical endpoints in hypertensive patients”)
2011 First Class Award for Excellent Paper, the 6th International Symposium on Pharmacoepidemiology and Clinical Rational Medication, Shanghai, China (for the paper “Analysis of the ADR signal and its impact factors induced by oral hypoglycemic agents”)
2007 Young Promising Key Teacher, Fudan University
2007 First Class Award for excellent paper, Academic Conference on Clinical Pharmacy, Chinese Pharmaceutical Association (for the paper “Antihypertensives and risk of hypoglycemia in elderly hypertensive diabetic patients using anti-diabetic drugs”)
2004 First Place, Excellent PRP Project Award, Shanghai Jiao Tong University
2001-2002 Doctoral Fellowship, Fudan University
1994-1997 Postgraduate Scholar, Anhui Medical University
1989-1994 Undergraduate Scholar, Anhui Medical University
Memberships
Editorial Board Member: Chinese Journal of Pharmacoepidemiology (2015-present)
Referee: Cochrane Database of Systematic Reviews
Chinese Journal of Clinical Pharmacy
Journal of Fudan University ( Medicine Edition)
Chinese Journal of Pharmacoepidemiology
Chinese Journal of New Drugs and Clinical Remedies
Member: Cochrane Hypertension Review Group of Cochrance Collaboration (Author)
Chinese Pharmacological Society
Specialty Committee of Pharmacoepidemiology, China
Chinese Pharmaceutical Association
Invited presentations
2015 National Academic Conference on Pharmacoepidemiology and Retrospect of Pharmacoepidemiologic Development in 20th Anniversary in China
Presentation Title: ”Evidence-based Pharmacotherapy of Intervention with Rennin-Angiotensin System Inhibitors to Prevent Clinical Endpoints in Hypertensive Patients”
2011 The Sixth International Symposium on Pharmacoepidemiology and Clinical Rational Drug Use in China.
Presentation Title: ”The Development Status, Evaluation Methodology and Future Direction of Pharmacoeconomics.”
Selected Publications（latest 5 yrs，<20 papers）
1. Chen YJ, Li LJ, Tang W*, Song JY, Qiu R, Li Q, Xue H, Wright JM. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension (Update). Cochrane Database of Systematic Reviews, 2018, in press.
2. Wang GM, Chen YJ, Li LJ, Tang WL*. Comparative analysis of renin angiotensin system (RAS) inhibitors and other antihypertensive agents in hypertensive patients with type 2 Diabetes Mellitus (T2DM): a systematic review and meta-analysis. Journal of Human Hypertension, 2018, in press
3. Li LJ, Chen YJ, Wang GM, Tang WL*, Wright JM. Renin inhibitors versus angiotensin receptor blockers for primary hypertension (Protocol). Cochrane Database of Systematic Reviews, 2017, Issue 2. Art. No.: CD012570.DOI: 10.1002/14651858.CD012570.
4. Wang GM, Li LJ, Chen YJ, Tang WL*, Wright JM. Renin inhibitors versus angiotensin converting enzyme inhibitors for primary hypertension (Protocol). Cochrane Database of Systematic Reviews, 2017, Issue 2. Art. No.: CD012569.DOI: 10.1002/14651858.CD012569.
5. Lu Z, Chen Y, Li L, Wang G, Xue H, Tang W*. Combination therapy of renin-angiotensin system inhibitors plus calcium channel blockers versus other two-drug combinations for hypertension: a systematic review and meta-analysis. Journal of Human Hypertension, 2017, 31(1): 1-13.
6. Li LJ, Chen YJ, Tang WL*. Transformation of Teaching Assistants' Roles in Pharmaceutical Education Based on MOOC. Chinese Journal of Clinical Pharmacy, 2017, 26(6): 409-413.
7. Tang WL. Exploration and practice of flipped classroom based on MOOC ‘antimicrobial and superbug’. Chinese Journal of Clinical Pharmacy, 2016, 25(4):247-250.
8. Xue H, Lu Z, Tang WL*, Pang LW, Wang GM, Wong GWK, Wright JM. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database of Systematic Reviews, 2015, Issue 1. Art. No.: CD008170.pub2. DOI: 10.1002/14651858.CD008170.pub2.
9. Tang WL. A new breakthrough in the reform of pharmacy teaching model based on MOOC. Chinese Journal of Clinical Pharmacy, 2015, 24(6): 378-380.
10. Pang L.W., Wang G.M., Tang W.L.*, Lu Z, Chen Y.J. Antihypertensive agents utilization among inpatients in five hospitals in Shanghai in 2011. Chinese Journal of Clinical Pharmacy, 2014, 23(6):361-365.
11. Tang WL*, Mao YC, Hong L. The Significance of Basic Medical Education for Pharmacy Students. Chinese Journal of Clinical Pharmacy, 2014, 23(4):256-258.
12. Tang W, He M, Yang B, Wei K, Yin M, Zhang L*. Association study of polymorphisms in the cyclooxygenase-2 gene and Alzheimer’s disease risk in Chinese. Neurological Sciences, 2013, 34 (5):695-699.
13. Zhao D, Tang W.L.*, Wang F. Analysis of influencing factors on observed regional difference in treatment effects in clinical trial. Chinese Journal of New Drugs and Clinical Remedies, 2013, 32 (11):876-879.
14. Yang P, Chen X.W., Tang W.L.*, Xue H, Lu Z. Oral hypoglycemic agents utilization among inpatients in five hospitals in Shanghai from 2007 to 2011. Chinese Journal of Clinical Pharmacy, 2013, 22(6):345-350.
